Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1996 Jun 1;183(6):2509-16.
doi: 10.1084/jem.183.6.2509.

Autoreactive cytotoxic T lymphocytes in human immunodeficiency virus type 1-infected subjects

F di Marzo Veronese  1 , D Arnott, V Barnaba, D J Loftus, K Sakaguchi, C B Thompson, S Salemi, C Mastroianni, A Sette, J Shabanowitz, D F Hunt, E Appella
Affiliations
Comparative Study

Autoreactive cytotoxic T lymphocytes in human immunodeficiency virus type 1-infected subjects

F di Marzo Veronese et al. J Exp Med. .

Abstract

A subtractive analysis of peptides eluted from major histocompatibility complex (MHC) class I human histocompatibility leukocyte antigen (HLA)-A2.1 molecules purified from either human immunodeficiency virus type-1 (HIV-1)-infected or uninfected cells was performed using micro high-performance liquid chromatography and mass spectrometry. Three peptides unique to infected cells were identified and found to derive from a single protein, human vinculin, a structural protein not known to be involved in viral pathogenesis. Molecular and cytofluorometric analyses revealed vinculin mRNA and vinculin protein overexpression in B and T lymphocytes from HIV-1-infected individuals. Vinculin peptide-specific CTL activity was readily elicited from peripheral blood lymphocytes of the majority of HLA-A2.1+, HIV+ patients tested. Our observations suggest that atypical vinculin expression and MHC class I-mediated presentation of vinculin-derived peptides accompany HIV infection of lymphoid cells in vivo, with a resultant induction of antivinculin CTL in a significant portion of HIV+ (HLA-A2.1+) individuals.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Virol. 1994 Sep;68(9):6103-10 - PubMed
    1. J Virol. 1994 Jul;68(7):4650-5 - PubMed
    1. J Exp Med. 1995 Jun 1;181(6):2253-7 - PubMed
    1. Nat Med. 1995 Apr;1(4):330-6 - PubMed
    1. Immunology. 1986 Jul;58(3):417-20 - PubMed

Publication types

MeSH terms